Revance Therapeutics, Inc. (RVNC)

Number of records: 50
SEC FilingInsiderCompanyTrade DateTransactionSharesAvg. PriceTotal% HoldingsReturn
15-Oct-19 8:23 PM
View: 
Foley Mark J
CEO & President
Director
Revance Therapeutics, Inc. (RVNC) 13-Oct-19Grant 200,000----597%
33.5K to 233.5K
18-Jul-19 8:29 PM
View: 
Nolet Chris
Director
Revance Therapeutics, Inc. (RVNC) 16-Jul-19Grant 9,000----100%
0 to 9.0K
02-Jul-19 9:16 PM
View: 
Schilke Tobin
CFO
Revance Therapeutics, Inc. (RVNC) 28-Jun-19Acquisition (other) 923$11.02$10,175.604%
23.0K to 23.92K
(< 1%)
02-Jul-19 9:15 PM
View: 
Browne L Daniel
CEO and President
Director
Revance Therapeutics, Inc. (RVNC) 28-Jun-19Acquisition (other) 1,000$11.02$11,024.50< 1%
151.6K to 152.6K
(< 1%)
02-Jul-19 9:14 PM
View: 
McDowell Caryn Gordon
SVP, GC & Secretary
Revance Therapeutics, Inc. (RVNC) 28-Jun-19Acquisition (other) 1,000$11.02$11,024.504%
22.93K to 23.93K
(< 1%)
17-Jun-19 8:30 PM
View: 
McDowell Caryn Gordon
SVP, GC & Secretary
Revance Therapeutics, Inc. (RVNC) 15-Jun-19Payment of Exercise 1,383$10.86$15,019.40(6%)
24.32K to 22.93K
(1%)
06-Jun-19 7:34 PM
View: 
Beraud Jill
Director
Revance Therapeutics, Inc. (RVNC) 04-Jun-19Grant 9,000----100%
0 to 9.0K
10-May-19 9:09 PM
View: 
Russell Angus C.
Director
Revance Therapeutics, Inc. (RVNC) 09-May-19Grant 4,500----75%
6.0K to 10.5K
10-May-19 9:11 PM
View: 
Vickers Philip J.
Director
Revance Therapeutics, Inc. (RVNC) 09-May-19Grant 4,500----49%
9.15K to 13.65K
10-May-19 9:05 PM
View: 
Gardner Phyllis
Director
Revance Therapeutics, Inc. (RVNC) 09-May-19Grant 4,500----75%
6.0K to 10.5K
10-May-19 8:54 PM
View: 
Gangolli Julian S
Director
Revance Therapeutics, Inc. (RVNC) 09-May-19Grant 4,500----75%
6.0K to 10.5K
10-May-19 8:52 PM
View: 
Foley Mark J
Director
Revance Therapeutics, Inc. (RVNC) 09-May-19Grant 4,500----16%
29.0K to 33.5K
10-May-19 8:49 PM
View: 
Byrnes Robert F
Director
Revance Therapeutics, Inc. (RVNC) 09-May-19Grant 4,500----23%
19.66K to 24.16K
19-Mar-19 9:01 PM
View: 
Browne L Daniel
CEO and President
Director
Revance Therapeutics, Inc. (RVNC) 18-Mar-19Market Sale (Planned) 11,613$15.51$180,068.00(7%)
163.22K to 151.6K
(3%)
19-Mar-19 8:58 PM
View: 
Allouche Cyril
Principal Accounting Officer
Revance Therapeutics, Inc. (RVNC) 18-Mar-19Market Sale (Planned) 498$15.48$7,709.04(7%)
6.9K to 6.4K
(3%)
19-Mar-19 9:01 PM
View: 
Browne L Daniel
CEO and President
Director
Revance Therapeutics, Inc. (RVNC) 15-Mar-19Payment of Exercise 6,137$15.45$94,816.60(4%)
169.35K to 163.22K
(4%)
19-Mar-19 8:58 PM
View: 
Allouche Cyril
Principal Accounting Officer
Revance Therapeutics, Inc. (RVNC) 15-Mar-19Payment of Exercise 252$15.45$3,893.40(4%)
7.15K to 6.9K
(4%)
18-Mar-19 8:34 PM
View: 
Joshi Abhay
Chief Operating Officer
Revance Therapeutics, Inc. (RVNC) 15-Mar-19Payment of Exercise 1,354$15.45$20,919.30(1%)
90.28K to 88.92K
18-Mar-19 8:34 PM
View: 
Joshi Abhay
Chief Operating Officer
Revance Therapeutics, Inc. (RVNC) 14-Mar-19Option Exercise 666$4.20$2,797.20< 1%
89.78K to 90.44K
18-Mar-19 8:34 PM
View: 
Joshi Abhay
Chief Operating Officer
Revance Therapeutics, Inc. (RVNC) 14-Mar-19Payment of Exercise 166$15.59$2,587.94(< 1%)
90.44K to 90.28K
20-Feb-19 9:31 PM
View: 
Browne L Daniel
CEO and President
Director
Revance Therapeutics, Inc. (RVNC) 19-Feb-19Market Sale (Planned) 5,446$17.68$96,285.30(3%)
174.8K to 169.35K
< 1%
20-Feb-19 9:33 PM
View: 
Joshi Abhay
Chief Operating Officer
Revance Therapeutics, Inc. (RVNC) 15-Feb-19Payment of Exercise 1,510$17.69$26,711.90(2%)
91.29K to 89.78K
< 1%
20-Feb-19 9:31 PM
View: 
Browne L Daniel
CEO and President
Director
Revance Therapeutics, Inc. (RVNC) 15-Feb-19Payment of Exercise 3,154$17.69$55,794.30(2%)
177.95K to 174.8K
< 1%
25-Jan-19 8:51 PM
View: 
Allouche Cyril
Principal Accounting Officer
Revance Therapeutics, Inc. (RVNC) 24-Jan-19Grant 3,150----79%
4.0K to 7.15K
25-Jan-19 8:49 PM
View: 
Joshi Abhay
Chief Operating Officer
Revance Therapeutics, Inc. (RVNC) 24-Jan-19Grant 15,750----21%
75.54K to 91.29K
25-Jan-19 8:54 PM
View: 
McDowell Caryn Gordon
SVP, GC & Secretary
Revance Therapeutics, Inc. (RVNC) 24-Jan-19Grant 7,500----45%
16.82K to 24.32K
25-Jan-19 9:00 PM
View: 
Schilke Tobin
CFO
Revance Therapeutics, Inc. (RVNC) 24-Jan-19Grant 5,000----28%
18.0K to 23.0K
25-Jan-19 9:02 PM
View: 
Browne L Daniel
CEO and President
Director
Revance Therapeutics, Inc. (RVNC) 24-Jan-19Grant 35,000----24%
142.95K to 177.95K
23-Jan-19 9:38 PM
View: 
Allouche Cyril
Principal Accounting Officer
Revance Therapeutics, Inc. (RVNC) 22-Jan-19Option Exercise 625$13.35$8,343.7516%
4.0K to 4.63K
23-Jan-19 9:38 PM
View: 
Allouche Cyril
Principal Accounting Officer
Revance Therapeutics, Inc. (RVNC) 22-Jan-19Market Option Sale (Planned) 625$17.77$11,106.20(14%)
4.63K to 4.0K
< 1%
17-Jan-19 8:55 PM
View: 
Joshi Abhay
Chief Operating Officer
Revance Therapeutics, Inc. (RVNC) 15-Jan-19Payment of Exercise 4,466$20.19$90,168.50(6%)
80.0K to 75.54K
12%
04-Jan-19 9:33 PM
View: 
Allouche Cyril
Principal Accounting Officer
Revance Therapeutics, Inc. (RVNC) 03-Jan-19Market Sale (Planned) 375$19.48$7,305.00(9%)
4.38K to 4.0K
9%
02-Jan-19 8:02 PM
View: 
Allouche Cyril
Principal Accounting Officer
Revance Therapeutics, Inc. (RVNC) 31-Dec-18Acquisition (other) 375$17.11$6,416.449%
4.0K to 4.38K
02-Jan-19 8:05 PM
View: 
McDowell Caryn Gordon
SVP, GC & Secretary
Revance Therapeutics, Inc. (RVNC) 31-Dec-18Acquisition (other) 818$17.11$13,996.405%
16.0K to 16.82K
14-Dec-18 9:23 PM
View: 
Joshi Abhay
Chief Operating Officer
Revance Therapeutics, Inc. (RVNC) 14-Dec-18Payment of Exercise 4,260$19.91$84,816.60(5%)
84.26K to 80.0K
11%
21-Nov-18 6:30 PM
View: 
Allouche Cyril
Principal Accounting Officer
Revance Therapeutics, Inc. (RVNC) 20-Nov-18Market Sale (Planned) 491$20.66$10,144.10(11%)
4.49K to 4.0K
14%
16-Nov-18 6:17 PM
View: 
Allouche Cyril
Principal Accounting Officer
Revance Therapeutics, Inc. (RVNC) 15-Nov-18Payment of Exercise 259$20.99$5,436.41(5%)
4.75K to 4.49K
16%
09-Nov-18 8:59 PM
View: 
Allouche Cyril
Principal Accounting Officer
Revance Therapeutics, Inc. (RVNC) 09-Nov-18Option Exercise 2,188$13.35$29,209.8046%
4.75K to 6.94K
09-Nov-18 8:59 PM
View: 
Allouche Cyril
Principal Accounting Officer
Revance Therapeutics, Inc. (RVNC) 09-Nov-18Market Option Sale (Planned) 2,188$23.72$51,899.40(32%)
6.94K to 4.75K
25%
07-Nov-18 8:31 PM
View: 
Schilke Tobin
CFO
Revance Therapeutics, Inc. (RVNC) 05-Nov-18Grant 18,000----100%
0 to 18.0K
17-Oct-18 6:53 PM
View: 
Zavodnick Todd Erik
CCO & President,
Revance Therapeutics, Inc. (RVNC) 15-Oct-18Payment of Exercise 7,093$23.94$169,806.00(7%)
103.5K to 96.41K
26%
06-Jul-18 9:17 PM
View: 
Allouche Cyril
Principal Financial Officer
Revance Therapeutics, Inc. (RVNC) 06-Jul-18Market Sale (Planned) 393$28.35$11,141.50(8%)
5.14K to 4.75K
38%
03-Jul-18 8:20 PM
View: 
Allouche Cyril
Principal Financial Officer
Revance Therapeutics, Inc. (RVNC) 29-Jun-18Acquisition (other) 393$23.33$9,169.678%
4.75K to 5.14K
03-Jul-18 8:17 PM
View: 
Browne L Daniel
CEO and President
Director
Revance Therapeutics, Inc. (RVNC) 29-Jun-18Acquisition (other) 668$23.33$15,586.10< 1%
142.28K to 142.95K
22-Jun-18 8:58 PM
View: 
Allouche Cyril
Principal Financial Officer
Revance Therapeutics, Inc. (RVNC) 20-Jun-18Grant 250----6%
4.5K to 4.75K
24-May-18 7:24 PM
View: 
Silvernail Lauren P
CFO & CBO
Revance Therapeutics, Inc. (RVNC) 22-May-18Market Sale (Planned) 2,874$30.25$86,924.40(4%)
68.37K to 65.5K
42%
11-May-18 8:27 PM
View: 
Gangolli Julian S
Director
Revance Therapeutics, Inc. (RVNC) 10-May-18Grant 3,000----100%
3.0K to 6.0K
11-May-18 8:28 PM
View: 
Gardner Phyllis
Director
Revance Therapeutics, Inc. (RVNC) 10-May-18Grant 3,000----100%
3.0K to 6.0K
11-May-18 8:26 PM
View: 
Foley Mark J
Director
Revance Therapeutics, Inc. (RVNC) 10-May-18Grant 3,000----12%
26.0K to 29.0K
11-May-18 8:24 PM
View: 
Byrnes Robert F
Director
Revance Therapeutics, Inc. (RVNC) 10-May-18Grant 3,000----18%
16.66K to 19.66K